abiraterone acetate + docetaxel + prednisone

abiraterone acetate + docetaxel + prednisone is a combination regimen used experimentally for the treatment of metastatic castration-sensitive and castration-resistant prostate cancer, especially in high-risk or de novo metastatic settings. **Abiraterone acetate** is a selective, irreversible inhibitor of the enzyme CYP17A1, leading to androgen biosynthesis inhibition. **Docetaxel** is a taxane-class chemotherapy that disrupts microtubule function, inducing cell death. **Prednisone** is a synthetic corticosteroid that serves as an anti-inflammatory and is used to counteract some side effects of the other drugs and, in abiraterone therapy, to suppress adrenocorticotropic hormone feedback. The three agents, when combined, target androgen production, mitotic division, and hormonal pathways, with evidence suggesting improved radiographic progression-free survival in metastatic castration-sensitive prostate cancer over standard of care. This regimen has been evaluated in studies such as the phase 1b COU-AA-206 study and the phase 3 PEACE-1 study, but is not yet a universally established or FDA-approved standard for use as a triplet outside of clinical trials for prostate cancer[1][4].

Brand names

TaxotereZytiga

Other names

docetaxel + prednisone + abiraterone acetate